Wire · operational-macro
Mirum Pharma Pill Lands FDA Approval for Ultra-Rare Bone Growth Disorder
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 27 September 2026 · Fusion42 review
The FDA approved Mirum Pharmaceuticals' oral drug Atebrioz (zilurgisertib) for treating fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder causing abnormal bone growth. This approval follows a secondary endpoint in clinical trials and adds to recently approved therapies for FOP and other rare diseases.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 25 Sep 2026 and 27 Sep 2026.
◆ ◆ The Wire takeaway
You must adjust to a rare disease market where oral drugs can outperform infusions on patient preference and age coverage. Mirum's pill opens earlier-stage FOP patients, changing who you sell to and how you position treatment options.
◆ Coverage
2 sources · first reported 25 Sep 2026 · latest 27 Sep 2026
◆ Related on Wire
◆ Topics